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Objective: The phosphoinositide 30-kinase (PI3K) e protein kinase B (AKT1) e glycogen synthase kinase
(GSK)-3b system is modulated by several factors implicated in the pathophysiology of schizophrenia.
Evidence suggests that neuregulin 1 (NRG1) induces decreased AKT phosphorylation in schizophrenia
relative to healthy controls, which may be related to dysfunctional neurodevelopment and neuro-
plasticity. The aim of this study was to investigate the relationship between NRG1 e induced AKT
phosphorylation and hippocampal volume in schizophrenia.
Methods: Participants were 20 ﬁrst-episode patients with schizophrenia who did not receive psycho-
tropic medications and 20 matched healthy controls. We measured the phosphorylated AKT e total AKT
and phosphorylated ERK (extracellular signal-regulated kinase) e total ERK ratios in peripheral
lymphoblasts before and after NRG1 administration. Whole-brain, left, and right hippocampal volumes
were quantiﬁed using FreeSurfer software.
Results: Patients with schizophrenia displayed decreased AKT but normal ERK ratio compared with
controls. Patients also had a reduction in left hippocampal volume. There was no signiﬁcant difference
between patients and controls in whole-brain and right hippocampal volume. Decreased AKT ratio was
associated with reduced hippocampal volume. There was no signiﬁcant relationship between ERK ratio
and brain structure.
Conclusion: Activation of the AKT system is speciﬁcally associated with hippocampal volume in ﬁrst-
episode schizophrenia, which provides further evidence for the pivotal role of this messenger system
in the pathophysiology of psychotic disorders.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
The complexity of the pathophysiology of schizophrenia and
related psychotic disorders raises important questions regarding
master regulator mechanisms integrating diverse molecular
factors. The phosphoinositide 30-kinase (PI3K) e protein kinase B
(AKT1) e glycogen synthase kinase (GSK)-3b intracellular signaling
system is modulated by dopamine, serotonin, glutamate, neu-
regulin 1 (NRG1), dysbindin, and Disrupted in Schizophrenia-1
(DISC-1), representing a reliable target for antipsychotics and
mood stabilizers (Kalkman, 2006; Bellon, 2007; Freyberg et al.,
2010; Karam et al., 2010; Kvajo et al., 2010; Beaulieu, 2011).
Recently, we found that a genome-wide association identiﬁedy of Medicine, Department of
zabolcs.gyula@med.u-szeged.
All rights reserved.psychosis risk variant of the CACNA1C gene, encoding the alpha
subunit of the L-type voltage-dependent calcium channel, also
affects the AKT system (Balog et al., 2010).
Regarding structural brain alterations, the hippocampusmay play
a critical role in schizophrenia because multiple pathophysiological
factors converge on this brain structure (Freedman and Goldowitz,
2010; Heckers and Conradi, 2010; Tamminga et al., 2010; Lodge and
Grace, 2011). Tan et al. (2011) reported that a schizophrenia-related
polymorphism of the AKT gene is linked to hippocampal structure
and function, with an epistasis with functional polymorphisms in
Brain Derived Neurotrophic Factor (BDNF) and Catechol-O-Methyl-
transferase (COMT) genes. Lower serum BDNF concentration corre-
lates with decreased hippocampal volume in ﬁrst-episode
schizophrenia (Rizos et al., 2011). Finally, poor sensory gating,
a putative marker of hippocampal dysfunction, is associated with
decreased NRG1-induced AKT activation in lymphoblasts of ﬁrst-
episode patients with schizophrenia (Kéri et al., 2010).
NRG1, a candidate susceptibility factor for psychotic disorders,
acts on Epidermal Growth Factor receptors (ErbBs) and plays an
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(Harrison and Law, 2006;Mei and Xiong, 2008; Schmitt et al., 2008;
Buonanno, 2010). Although genome-wide association studies did
not conﬁrm its association with psychotic disorders (O’Donovan
et al., 2008; The Schizophrenia Psychiatric Genome-Wide Associ-
ation Study Consortium, 2011), gene expression proﬁles of neurons
derived from reprogrammed ﬁbroblasts of schizophrenia patients
into human pluripotent stem cells revealed abnormal patterns of
NRG1 expression (Brennand et al., 2011). Sei et al. (2007) investi-
gated NRG1-induced migration of lymphoblasts and demonstrated
decreased migration in patients with schizophrenia relative to
controls. From a genetic point of view, the magnitude of NRG1-
induced lymphoblast migration was associated with poly-
morphisms of the NRG1, COMT, and AKT genes (Sei et al., 2007,
2010), and NRG1 risk polymorphisms are associated with
decreased hippocampal volume (Gruber et al., 2008).
One of the master regulator mechanisms responsible for
impaired lymphoblast migration may be decreased AKT phos-
phorylation in patients with schizophrenia (Sei et al., 2007).
Decreased AKT phosphorylation in lymphoblasts of patients is also
related to diminished suppression of the P50 event-related
potential (Kéri et al., 2010), impaired habituation of autonomic
arousal, and delusional ideations in non-clinical individuals (Kéri
et al., 2011). However, it is not known whether AKT activation is
linked to structural alterations of the hippocampus, which is
implicated in various intermediate phenotypes and clinical
symptoms of schizophrenia (Freedman and Goldowitz, 2010;
Heckers and Conradi, 2010; Tamminga et al., 2010; Lodge and
Grace, 2011). To answer this question, we measured NRG1-
induced activation of intracellular messenger systems in periph-
eral lymphoblasts of schizophrenia patients and controls, and
calculated correlations with volumes of brain structures. In addi-
tion to the AKT system, we also investigated NRG1-induced
phosphorylation of ERK (extracellular signal-regulated kinase) in
order to test the speciﬁcity of potential relationship with brain
structure (Sei et al., 2007).2. Methods
2.1. Participants
Twenty patients with ﬁrst-episode schizophrenia and twenty
healthy controls participated in the study. The patients had a ﬁrst
episode of schizophrenia and did not receive psychotropic medi-
cations. The control participants were hospital employees, their
spouses, and acquaintances. All participants received the Struc-
tured Clinical Interview for DSM-IV axis I disorders (SCID-CV) (First
et al., 1996). The control participants had no Axis I psychiatric
disorders and had a negative family history for psychotic disorders.
Detailed medical records were available from each patient,
including reports from parents and other relatives. ExclusionTable 1
Clinical and demographic description of the participants.
Controls (n ¼ 20) 13 male/7
Mean SD
Age (years) 24.7 6.2
Education (years) 11.5 4.5




PANSS e Positive and Negative Syndrome Scale. Controls and patients did not differ in acriteria included neurological disorders, head injury, history of
psychoactive substance dependence, and positive toxicological
screening. For the assessment of clinical symptoms, we used the
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987).
Table 1 presents the clinical and demographic characteristics. The
study was carried out in accordance with the Declaration of Hel-
sinki and was approved by the local ethics board. All participants
were able to give written informed consent.
2.2. AKT and ERK phosphorylation
We used standard methods reported previously (Sei et al., 2007,
2010; Kéri et al., 2009, 2010, 2011). B lymphocytes in the mono-
nuclear cell preparation were transformed by EpsteineBarr virus.
The lymphoblasts were stimulated with NRG1A for 30 min. We
performedWestern blots to analyze proteins isolated from the cells.
To quantify phosphorylation, the immunoblots were stained with
antibodies speciﬁc to phosphorylated ERK (Tyr180; 42, 44 kDa) or
AKT (Ser473; 60 kDa) and were then stripped and probed with
antibodies to total ERK or AKT. The primary antibodies were
detected using horseradish peroxidase-conjugated anti-rabbit IgG
antibodies. We measured the relative optical density using the
National Institute of Health Image software. The dependent
measure was the ratio of phosphorylated AKT (pAKT) or phos-
phorylated ERK (pERK) and total AKT or total ERK at baseline
(without NRG1 stimulation) and after NRG1 stimulation.
2.3. Structural brain imaging
Each participant underwent a head magnetic resonance (MR)
imaging (Philips Intera 1.5 T scanner; T1-weighted 3D/FFE
gradient-echo sequence, TR/TE 14.3/3.3 ms, ﬂip angle 30, ﬁeld of
view 240, matrix 256  256, slab thickness 2 mm, 1.5 mm spacing,
124e130 partitions, inplane resolution: 0.94  0.94 mm). We used
the validated standard FreeSurfer image analysis pipeline (Martinos
Center for Biomedical Imaging, Boston, MA, USA; http://surfer.nmr.
mgh.harvard.edu/). Image processing included the removal of non-
brain tissue with a hybrid watershed/surface deformation proce-
dure, automated Talairach transformation, and segmentation of the
subcortical white and gray matter (Fischl et al., 2004; Segonne
et al., 2004). We measured whole-brain, right, and left hippo-
campal volume.
2.4. Data analysis
We used STATISTICA 9 (StatSoft, Inc., Tulsa) software for data
analysis. The normality of data distribution and the homogeneity of
variance were checked using KolmogoroveSmirnov and Levene’s
tests, respectively. We conducted repeated measures analyses of
variance (ANOVAs), followed by Scheffé’s post hoc tests, or two-
tailed t tests to compare patients and controls. We calculatedfemale Schizophrenia (n ¼ 20) 13 male/7 female
range Mean SD range
19e30 24.3 5.4 19e29





ge and education (p > 0.5, t test) and were matched for gender ratio.
Fig. 1. Mean phosphorylated AKT/total AKT and phosphorylated ERK/total ERK ratios in patients with schizophrenia (SCZ) and healthy controls (CONT). Immunoblots represent
samples from the NRG1-induced condition. Error bars indicate 95% conﬁdence intervals. *p < 0.001, Scheffé’s test.
A. Szamosi et al. / Journal of Psychiatric Research 46 (2012) 279e284 281Pearson’s product moment correlation coefﬁcients and used linear
regression analysis to determine associations between AKT/ERK
ratios and brain volume. The level of signiﬁcance was set at
a < 0.05.
3. Results
3.1. AKT and ERK ratios
Fig. 1 depicts the AKT and ERK ratios (phosphorylated protein/
total protein) at baseline and after NRG1 stimulation. We con-
ducted an ANOVA in which group was the between-subjects factor
and ratio (AKT vs. ERK), and condition (baseline vs. NRG1 stimu-
lation) were the within-subjects factors. The ANOVA revealed
signiﬁcant main effects of group (F(1,38) ¼ 24.46, p < 0.001), ratio
(F(1,38) ¼ 26.37, p < 0.001), and condition (F(1,38) ¼ 30.16,
p < 0.001). There were signiﬁcant two-way interactions between
group and ratio (F(1,38) ¼ 6.34, p < 0.05), and group and condition
(F(1,38) ¼ 12.71, p < 0.01). The three-way interaction among group,
ratio, and conditionwas also signiﬁcant (F(1,38)¼ 19.71, p< 0.001).
Scheffé’s tests revealed a single condition in which the values
were signiﬁcantly lower in patients relative to controls: the NRG1-
induced AKT ratio (p < 0.001) (Fig. 1).
3.2. Brain volumes
Table 2 presents the results from brain volume measurements.
Patients displayed signiﬁcantly reduced left hippocampal volume
relative to controls, whereas in the case of right hippocampus and
whole-brain volume the difference did not reach the level of
statistical signiﬁcance.Table 2
Hippocampal and whole-brain volumes.
Controls (n ¼ 20) Schizophrenia (n ¼
Left hippocampus (mm3) 3566.0 (292.1) 3354.5 (227.6)
Right hippocampus (mm3) 3627.5 (285.1) 3480.5 (227.7)
Whole-brain (cm3) 1325.0 (119.4) 1295.1 (104.2)
Data are mean (SD). Results from two-tailed t tests (df ¼ 38) and effect size values (Coh3.3. Correlations between molecular markers and brain structure
Table 3 presents the correlation coefﬁcients between AKT and
ERK ratios and brain volumes in patients with schizophrenia. Left
and right hippocampal volumes correlated with NRG1-induced
AKT activation (Fig. 2). In the control group, the correlations were
not signiﬁcant, but in the case of hippocampus there was a positive
relationship similar to that observed in patients with schizophrenia
(r[left] ¼ 0.31, p ¼ 0.3; r[right] ¼ 0.28, p ¼ 0.4).
We further examined the relationship between hippocampal
volume and NRG1-induced AKT activation in schizophrenia patients
using linear regression analysis with age, education, gender, symp-
toms (PANSS scores), and whole-brain volume. For both left and
right hippocampi, only AKT activation was a signiﬁcant predictor
(left: b* ¼ 0.54, t(13) ¼ 2.23, p < 0.05; right: b* ¼ 0.62, t(13) ¼ 2.64,
p < 0.05).4. Discussion
The results of the present study revealed that diminished NRG1-
induced AKT phosphorylation in peripheral lymphoblasts is asso-
ciated with smaller hippocampal but not whole-brain volume in
schizophrenia. In contrast, ERK phosphorylation was not related to
brain structure and did not show abnormality in schizophrenia.
ERKs, also called mitogen-activated protein kinases (MAPKs), are
ubiquitous intracellular signaling molecules modulated by various
growth factors and neurotransmitters, regulating cell division,
differentiation, and metabolism (Keshet and Seger, 2010). Given
that this systemwas intact in schizophrenia, our results are against
the possibility of a generalized dysfunction of widespread intra-
cellular messenger systems. Furthermore, we investigated ﬁrst-20) t p d Decrease in patients
2.55 0.01 0.75 6%
1.80 0.08 0.55 4%
0.86 0.39 0.27 2%
en’s d) are shown.
Table 3
Correlations among AKT/ERK ratios and brain structure in patients with schizo-







AKT baseline 0.17 0.27 0.16
AKT NRG1-induced 0.52* 0.61* 0.01
ERK baseline 0.12 0.09 0.11
ERK NRG1-induced 0.18 0.02 0.07
The table depicts Pearson’s product moment correlation coefﬁcients. *p < 0.05.
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and therefore the confounding effect of drugs and adversity
accompanying disease chronicity can be excluded. Although
impaired AKT activation seems to be similar in ﬁrst-episode and
chronic patients (Kéri et al., 2009, 2010), longitudinal studies are
warranted to explore the effects of medications and illness course.
Mechanisms associated with neurodevelopment and neuro-
plasticity could explain why impaired NRG1-induced AKT activation
might affect hippocampal structure. According to Bellon (2007),
NRG1 and AKT are important in neurite formation, a crucial stage in
development, which may be impaired in schizophrenia. NRG1 is
a key regulator in the development of GABA-ergic neuronal circuits
(Fazzari et al., 2010; Ting et al., 2011). There is increasing evidence
that NRG1 in the peripheral circulation inﬂuences postnatal neuro-
development and neuroplasticity, and these processes are related to
GABA-ergic interneurons and their glutamatergic innervation (Abe
et al., 2011). Rösler et al. (2011) showed that the extracellular
domain of peripheral NRG1 passes the bloodebrain barrier and
activates receptors in the brain. In adult mice, peripherally admin-
istered NRG1 enhanced neurogenesis in the hippocampus (Mahar
et al., 2011). Our results may provide a link between basic and
clinical neuroscience, motivating future studies to assess the cellular
correlates of brain volume loss in schizophrenia and its relationship
with speciﬁc cell types in the hippocampus and prefrontal cortex
(Lewis and González-Burgos, 2008; Lisman et al., 2008).
It is important to emphasize that our results are indirect, as there
is no evidence that NRG1-induced AKT phosphorylation is the sameFig. 2. Correlation between left hippocampal volume (open circles, continuous line; r ¼ 0.5
phosphorylated AKT/total AKT ratio.in neurons and peripheral lymphoblasts. However,Balu et al. (2010)
examined postmortem tissue from patients with schizophrenia and
showed decreased phosphorylated AKT levels in the dentate gyrus,
the neurogenic zone of the hippocampus. Nevertheless, correlation
data between peripheral markers and brain structures must be
treated with caution and need to be replicated and extended in
studies allowing conclusions based on causal relationships.
It is also not fully clariﬁed whether NRG1-induced AKT activation
is illness state-dependent or reﬂects a trait affecting early circuit
formation in the hippocampus before the appearance of psychotic
symptoms. In a small group of monozygotic twins discordant for
schizophrenia, we found abnormal AKT activation only in affected
twins but not in healthy co-twins, although the healthy co-twins’
activation level was lower than that of the unrelated controls
(Seres et al., 2010). If AKT activation is a state-marker, it may be
related to other aspects of neuroplasticity, such as dendritic arbori-
zation, cell size, and probably cell division. Chakos et al. (2005)
demonstrated that decreased hippocampal volume is not merely
a stable trait marker of schizophrenia. Speciﬁcally, they showed that
in an early illness group second-generation antipsychotics were
associated with larger hippocampal volumes (Chakos et al., 2005).
The exact cellular mechanism of this effect is not clear, but the AKT
systemmay be a candidatemediating the effects of antipsychotics on
neuroplasticity (Freyberg et al., 2010).
Decreased hippocampal volume is one of the most frequently
reported structural brain abnormality in schizophrenia (Nelson et al.,
1998; Wright et al., 2000; Honea et al., 2005; Steen et al., 2006; Vita
et al., 2006; Adriano et al., 2011) although its disease speciﬁcity is
low, and its magnitude is moderate and variable across studies
(Geuze et al., 2005). For example, Steen et al. (2006) reported
hippocampal volume deﬁcit of 8% in ﬁrst-episode patients, whereas
Nelson et al. (1998) found much smaller volume loss in chronic
patients (4%), which can be considered as a paradoxical ﬁnding. It is
notable, however, that 4% volume difference is within the range of
“machine drift”, which is due to various factors including voxel
misclassiﬁcation, partial volume effect, and head tilt (Steen et al.,
2006). There is meta-analytic evidence for hippocampal volume
reduction in ﬁrst-episode schizophrenia (Steen et al., 2006; Vita1), right hippocampal volume (ﬁlled circles, dotted line; r ¼ 0.62), and NRG1-induced
A. Szamosi et al. / Journal of Psychiatric Research 46 (2012) 279e284 283et al., 2006; Adriano et al., 2011), and others identiﬁed volume loss in
the uncus/amygdala complex (Ellison-Wright et al., 2008). Recent
studies found hippocampal volume reduction not only in ﬁrst-
episode schizophrenia, but also in “high-risk” individuals with
prodromal symptoms (Ebdrup et al., 2010; Witthaus et al., 2010; for
a review of “high-risk” studies, see Fusar-Poli et al., 2011), although
others suggested that hippocampal volume loss is associated with
the ﬁrst psychotic episode (Buehlmann et al., 2010).
Despite the fact that we demonstrated a speciﬁc molecular
correlate of hippocampal volume reduction, it is important to note
that non-speciﬁc factors may also account for such deﬁcits.
Mondelli et al. (2010) reported that higher cortisol levels, a marker
of general stress response, are associated with smaller left hippo-
campus in ﬁrst-episode psychosis. The confounding effect of such
non-speciﬁc factors should be investigated by future studies.
The most important limitations of the present study are small
sample size and MR scanning at 1.5 T. Slab thickness and spacing
between slabs do not allowa high-resolutionmapping and a proper
investigation of hippocampal subregions. Moreover, it is essential
to clarify how antipsychotics modulate the AKT system in ﬁrst-
episode patients, and how it relates to longitudinal structural
changes of the hippocampal formation and other brain structures.
In conclusion, peripheral markers of impaired intracellular
signaling processes may be putative markers of schizophrenia.
These molecular alterations speciﬁcally correlate with structural
brain changes. Our data indicate that the relationship between
NRG1-induced AKT phosphorylation and hippocampal structure
and function (Kéri et al., 2010) may be especially relevant.
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